India's Suven Life doses first subjects in cognitive disorder drug trial; stock up

Suven Life Sciences

08/01/2025 08:32

** Suven Life Sciences  SUVP.NS  rises as much as 14.3% to
144.4 rupees, highest since Dec. 20, 2024
    ** Pharma co says the first subjects of SUVN-I6107's Phase 1
clinical trial have been dosed; SUVN-I6107 is used to treat
cognitive disorders
    ** Adds study's primary objective is to assess drug's safety
and tolerability
    ** Stock gains 8% so far this week
    ** More than 1 mln shares traded, 3.3x the 30-day avg, in
stock's busiest day since Dec. 10, 2024
    ** SUVP gained 58.4% in 2024 - second consecutive year of
gains

 (Reporting by Meenakshi Maidas in Bengaluru)
 ((meenakshi.maidas@thomsonreuters.com;))